Chemo-loaded microspheres aim to starve liver tumors from within

NCT ID NCT05911633

Recruiting now Disease control Sponsor: Terumo Europe N.V. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the drug directly into the cancer. The study will check how safe this is and whether it can shrink or control the tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: doxorubicin-loaded BioPearl microspheres
What this could lead to: If successful, this could offer a safe and effective way to deliver chemotherapy directly to liver tumors, potentially improving tumor control without major surgery.
What could go wrong: This is a small, single-arm study with no comparison group, so results may not be definitive. Risks include side effects from the chemotherapy or procedure, such as liver damage or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-RESECTABLE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beaujon Hospital
RECRUITING

Clichy, France

Contact Email: •••••@•••••
CHU Grenobles (Hôpital Michallon)
NOT_YET_RECRUITING

La Tronche, France

Contact Email: •••••@•••••
CUB Hôpital Erasme
RECRUITING

Brussels, Belgium

Contact Email: •••••@•••••
Città della Salute e della Scienza di Torino
RECRUITING

Turin, Italy

Contact Email: •••••@•••••
Fondazione IRCCS Instituto Tumori
RECRUITING

Milan, Italy

Contact Email: •••••@•••••
Fondazione Policlinico Universitario A. Gemelli
RECRUITING

Rome, Italy

Contact Email: •••••@•••••
Paul-Brousse Hospital
RECRUITING

Villejuif, France

Contact Email: •••••@•••••
SLK-Kliniken Heilbronn
RECRUITING

Heilbronn, Germany

Contact Email: •••••@•••••
UZ Leuven
RECRUITING

Leuven, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital Tübingen
RECRUITING

Tübingen, Germany

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.